We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Siemens Healthineers - Laboratory Diagnostics

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App




Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

By LabMedica International staff writers
Posted on 10 Aug 2023
Print article
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality and morbidity globally. In a significant advancement, two novel assays are now available for use with other lab tests and clinical evaluations to assist in evaluating the risk of pregnant women, already admitted for hypertension-related pregnancy disorders, developing severe preeclampsia within the upcoming two weeks.

Thermo Fisher Scientific Inc. (Waltham, MA; USA) has been granted clearance by the U.S. Food and Drug Administration (FDA) for its novel biomarkers, Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR. These are the first and only immunoassays to secure breakthrough designation and clearance for preeclampsia risk evaluation and treatment. The PRAECIS study, which validated the efficacy of these blood-based biomarkers in the detection of the development of severe preeclampsia, was conducted across 18 U.S. hospitals and involved over 700 expectant mothers nationwide. Women exhibiting a positive result based on the risk ratio of both assays (sFlt-1/PlGF ratio ≥ 40) can benefit from enhanced surveillance and accelerated care ahead of the onset of severe symptoms.

The assays are designed to run on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS clinical chemistry analyzer which uses Nobel Prize-winning TRACE chemistry technology to deliver results in under 30 minutes. The FDA clearance and availability of these pioneering biomarker tests empower healthcare professionals to improve their management of the condition and enhance outcomes for mothers and their babies. Both patients and medical providers stand to gain from these improved diagnostic tools that can predict the onset of severe preeclampsia, particularly in cases at risk of severe, early-onset disease or for women with diagnostic uncertainty.

“Thermo Fisher is committed to advancing diagnostic solutions for reproductive health as part of our broader Mission to enable our customers to make the world healthier, cleaner and safer,” said Alan Sachs, chief medical officer at Thermo Fisher Scientific. “Today’s clearance of these breakthrough biomarkers will have a significant impact on prognosis and treatment for thousands of women at risk for preeclampsia every year in the U.S.”

Related Links:
Thermo Fisher Scientific Inc

New
Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
New
Gold Supplier
D-Dimer Test
Epithod 616 D-Dimer Kit
New
Total Thyroxine (T4) Test
Neonatal T4 ELISA Kit
New
Tuberculosis Antibody Test
Tuberculosis lgG/lgM Rapid Test

Print article
GLOBETECH PUBLISHING LLC

Channels

Molecular Diagnostics

view channel
Image: A CRISPR technology-based diagnostic test detects MPXV in clinical samples with acute precision (Photo courtesy of 123RF)

Powerful Diagnostic Tool Accurately Detects Monkeypox Virus Faster Than Any Method

At present, testing for the monkeypox virus (MPXV) is done mainly in centralized labs, and it can take days to get results due to location and logistical issues. Now, researchers have leveraged cutting-edge... Read more

Hematology

view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more

Immunology

view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more

Microbiology

view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more

Pathology

view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.